Annual EBITDA
-$26.09 M
+$33.45 M+56.19%
31 December 2023
Summary:
ProQR Therapeutics NV annual earnings before interest, taxes, depreciation & amortization is currently -$26.09 million, with the most recent change of +$33.45 million (+56.19%) on 31 December 2023. During the last 3 years, it has risen by +$21.99 million (+45.73%). PRQR annual EBITDA is now -515.58% below its all-time high of -$4.24 million, reached on 31 December 2013.PRQR EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$8.98 M
-$5.70 M-173.92%
01 September 2024
Summary:
ProQR Therapeutics NV quarterly earnings before interest, taxes, depreciation & amortization is currently -$8.98 million, with the most recent change of -$5.70 million (-173.92%) on 01 September 2024. Over the past year, it has dropped by -$1.63 million (-22.22%). PRQR quarterly EBITDA is now -666.09% below its all-time high of $1.59 million, reached on 31 December 2015.PRQR Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$20.59 M
-$1.63 M-8.61%
01 September 2024
Summary:
ProQR Therapeutics NV TTM earnings before interest, taxes, depreciation & amortization is currently -$20.59 million, with the most recent change of -$1.63 million (-8.61%) on 01 September 2024. Over the past year, it has increased by +$10.91 million (+34.63%). PRQR TTM EBITDA is now -1677.61% below its all-time high of -$1.16 million, reached on 30 September 2013.PRQR TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
PRQR EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +56.2% | -22.2% | +34.6% |
| 3 y3 years | +45.7% | +46.7% | +66.8% |
| 5 y5 years | +37.4% | +37.6% | +64.2% |
PRQR EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +59.9% | -2765.7% | +53.8% | -8.6% | +71.6% |
| 5 y | 5 years | at high | +59.9% | -2765.7% | +53.8% | -8.6% | +71.6% |
| alltime | all time | -515.6% | +59.9% | -666.1% | +53.8% | -1677.6% | +71.6% |
ProQR Therapeutics NV EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$8.98 M(+173.9%) | -$20.59 M(+8.6%) |
| June 2024 | - | -$3.28 M(-59.1%) | -$18.96 M(-23.2%) |
| Mar 2024 | - | -$8.02 M(+2459.2%) | -$24.68 M(-5.6%) |
| Dec 2023 | -$26.09 M(-56.2%) | -$313.40 K(-95.7%) | -$26.16 M(-17.0%) |
| Sept 2023 | - | -$7.35 M(-18.4%) | -$31.50 M(-27.7%) |
| June 2023 | - | -$9.00 M(-5.2%) | -$43.58 M(-14.4%) |
| Mar 2023 | - | -$9.49 M(+67.8%) | -$50.92 M(-15.0%) |
| Dec 2022 | -$59.54 M(-8.4%) | -$5.66 M(-70.9%) | -$59.91 M(-17.5%) |
| Sept 2022 | - | -$19.43 M(+18.9%) | -$72.58 M(+3.7%) |
| June 2022 | - | -$16.34 M(-11.6%) | -$70.01 M(+0.9%) |
| Mar 2022 | - | -$18.49 M(+0.9%) | -$69.35 M(+7.2%) |
| Dec 2021 | -$65.01 M(+35.2%) | -$18.33 M(+8.7%) | -$64.69 M(+4.4%) |
| Sept 2021 | - | -$16.86 M(+7.5%) | -$61.98 M(+8.1%) |
| June 2021 | - | -$15.68 M(+13.4%) | -$57.36 M(+5.5%) |
| Mar 2021 | - | -$13.82 M(-11.5%) | -$54.34 M(-6.5%) |
| Dec 2020 | -$48.07 M(-19.7%) | -$15.62 M(+27.6%) | -$58.13 M(+1.2%) |
| Sept 2020 | - | -$12.23 M(-3.4%) | -$57.45 M(-3.6%) |
| June 2020 | - | -$12.67 M(-28.1%) | -$59.61 M(-0.1%) |
| Mar 2020 | - | -$17.61 M(+17.9%) | -$59.66 M(+2.5%) |
| Dec 2019 | -$59.87 M | -$14.94 M(+3.8%) | -$58.20 M(+1.1%) |
| Sept 2019 | - | -$14.39 M(+13.2%) | -$57.59 M(+15.6%) |
| June 2019 | - | -$12.72 M(-21.3%) | -$49.80 M(+5.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2019 | - | -$16.15 M(+12.7%) | -$47.11 M(+8.6%) |
| Dec 2018 | -$41.66 M(-12.4%) | -$14.33 M(+117.2%) | -$43.39 M(+0.3%) |
| Sept 2018 | - | -$6.60 M(-34.2%) | -$43.26 M(-10.0%) |
| June 2018 | - | -$10.03 M(-19.3%) | -$48.08 M(-2.0%) |
| Mar 2018 | - | -$12.43 M(-12.5%) | -$49.07 M(+3.6%) |
| Dec 2017 | -$47.58 M(+15.2%) | -$14.20 M(+24.4%) | -$47.37 M(+15.6%) |
| Sept 2017 | - | -$11.42 M(+3.6%) | -$40.99 M(+0.5%) |
| June 2017 | - | -$11.02 M(+2.8%) | -$40.78 M(-1.5%) |
| Mar 2017 | - | -$10.72 M(+37.0%) | -$41.41 M(+3.3%) |
| Dec 2016 | -$41.30 M(+86.5%) | -$7.83 M(-30.1%) | -$40.09 M(+30.7%) |
| Sept 2016 | - | -$11.20 M(-3.9%) | -$30.67 M(+11.1%) |
| June 2016 | - | -$11.66 M(+24.0%) | -$27.62 M(+20.2%) |
| Mar 2016 | - | -$9.40 M(-692.6%) | -$22.97 M(+7.1%) |
| Dec 2015 | -$22.15 M(+41.9%) | $1.59 M(-119.5%) | -$21.45 M(-8.4%) |
| Sept 2015 | - | -$8.15 M(+16.3%) | -$23.41 M(+8.2%) |
| June 2015 | - | -$7.00 M(-11.2%) | -$21.64 M(+2.1%) |
| Mar 2015 | - | -$7.88 M(+2025.8%) | -$21.19 M(+33.8%) |
| Dec 2014 | -$15.61 M(+268.3%) | -$370.90 K(-94.2%) | -$15.83 M(-9.3%) |
| Sept 2014 | - | -$6.38 M(-2.9%) | -$17.45 M(+42.6%) |
| June 2014 | - | -$6.56 M(+159.9%) | -$12.24 M(+115.7%) |
| Mar 2014 | - | -$2.52 M(+26.9%) | -$5.67 M(+80.2%) |
| Dec 2013 | -$4.24 M | -$1.99 M(+71.8%) | -$3.15 M(+171.8%) |
| Sept 2013 | - | -$1.16 M | -$1.16 M |
FAQ
- What is ProQR Therapeutics NV annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for ProQR Therapeutics NV?
- What is ProQR Therapeutics NV annual EBITDA year-on-year change?
- What is ProQR Therapeutics NV quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for ProQR Therapeutics NV?
- What is ProQR Therapeutics NV quarterly EBITDA year-on-year change?
- What is ProQR Therapeutics NV TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for ProQR Therapeutics NV?
- What is ProQR Therapeutics NV TTM EBITDA year-on-year change?
What is ProQR Therapeutics NV annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of PRQR is -$26.09 M
What is the all time high annual EBITDA for ProQR Therapeutics NV?
ProQR Therapeutics NV all-time high annual earnings before interest, taxes, depreciation & amortization is -$4.24 M
What is ProQR Therapeutics NV annual EBITDA year-on-year change?
Over the past year, PRQR annual earnings before interest, taxes, depreciation & amortization has changed by +$33.45 M (+56.19%)
What is ProQR Therapeutics NV quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of PRQR is -$8.98 M
What is the all time high quarterly EBITDA for ProQR Therapeutics NV?
ProQR Therapeutics NV all-time high quarterly earnings before interest, taxes, depreciation & amortization is $1.59 M
What is ProQR Therapeutics NV quarterly EBITDA year-on-year change?
Over the past year, PRQR quarterly earnings before interest, taxes, depreciation & amortization has changed by -$1.63 M (-22.22%)
What is ProQR Therapeutics NV TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of PRQR is -$20.59 M
What is the all time high TTM EBITDA for ProQR Therapeutics NV?
ProQR Therapeutics NV all-time high TTM earnings before interest, taxes, depreciation & amortization is -$1.16 M
What is ProQR Therapeutics NV TTM EBITDA year-on-year change?
Over the past year, PRQR TTM earnings before interest, taxes, depreciation & amortization has changed by +$10.91 M (+34.63%)